Cambridge Innovation Capital has backed the series B round, alongside other investors that included Parkwalk Advisors.
Congenica, a provider of clinical genome analysis technology spun out of charitable foundation Wellcome Trust, received £8m ($10m) in series B funding on Monday from investors including Cambridge Innovation Capital (CIC).
CIC, Cambridge University’s venturing fund, participated alongside spinout-focused investment firm Parkwalk Advisors and VC firm Amadeus Capital Partners.
Congenica is commercialising research conducted at Wellcome Trust’s Sanger Institute. The spinout is working on a platform, called Sapientia, that enables clinicians to gain actionable insight into genetic diseases.
The company…
